<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>


HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. HLS Therapeutics listed publicly on the TSXV in March 2018 by way of a reverse takeover of Automodular Corporation. On February 7, 2019, HLS Therapeutics graduated from the TSXV and its shares began trading on the TSX exchange.

Monday, April 1, 2019

View All


The information contained on the Investor Relations section of this website was accurate at the time of posting, but may be superseded by subsequent disclosures. Please check the date of the material posted.

Mar 29, 2019

Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center...

Mar 21, 2019

Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®,...

Mar 19, 2019

Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics...

Read More